-
MITSUBISHI TANABE PHARMA CORPORATION et al v. PRINSTON PHARMACEUTICALS, INC. DC
- 1:17-cv-07342
- D.N.J.
- Judge: Renee Marie Bumb
+1
- Filed: 09/21/2017
- Closed: 06/19/2019
- Latest Docket Entry: 01/28/2021
- PACER
- Docket updated daily
5
Plaintiffs
1
Defendant
2
Accused
Products
1
Patent-in-Suit
637
Days in
Litigation
-
MITSUBISHI TANABE PHARMA CORPORATION et al v. PRINSTON PHARMACEUTICALS, INC. DC
- 1:17-cv-07342
- D.N.J.
- Judge: Renee Marie Bumb
+1
- Filed: 09/21/2017
- Closed: 06/19/2019
- Latest Docket Entry: 01/28/2021
- PACER
- Docket updated daily
Cause of Action
Infringement
Assigned Judge
Outcome Summary
- Patent Information
-
Infringement
Hetero Labs Limited
- 1 Detail
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| INVOKANA® 100 mgINVOKANA® 300 mg | US 8,513,202 B2 | All Asserted Claims |
Infringement
Entry 13
|
Hetero Labs Limited Unit V
- 1 Detail
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| INVOKANA® 100 mgINVOKANA® 300 mg | US 8,513,202 B2 | All Asserted Claims |
Infringement
Entry 13
|
Hetero USA Incorporated
- 1 Detail
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| INVOKANA® 100 mgINVOKANA® 300 mg | US 8,513,202 B2 | All Asserted Claims |
Infringement
Entry 13
|
Laurus Labs Limited
- 1 Detail
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| Generic version of canagliflozin tablets | US 8,513,202 B2 | All Asserted Claims |
Infringement
Entry 17
|
Lupin Limited
- 1 Detail
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| Pharmaceutical products asserted to be bioequivalent to the Invokana, Invokamet, and Invokamet XR Products | US 8,513,202 B2 | All Asserted Claims |
Infringement
Entry 19
|
Lupin Pharmaceuticals Incorporated
- 1 Detail
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| Pharmaceutical products asserted to be bioequivalent to the Invokana, Invokamet, and Invokamet XR Products | US 8,513,202 B2 | All Asserted Claims |
Infringement
Entry 19
|
Prinston Pharmaceutical Incorporated
- 1 Detail
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| Generic canagliflozin tablet 100 mgGeneric canagliflozin tablet 300 mgINVOKANA® 100 mgINVOKANA® 300 mg | US 8,513,202 B2 | All Asserted Claims |
Infringement
Entry 16Entry 26 |
